Kawalec P, et al. - This study involves comparison of novel biologic therapies for psoriatic arthritis (PsA) and determination of the place of non-anti-tumor necrosis factor α (TNF-α) biologic drugs in the treatment regimen of the disease. Researchers reported, based on the findings, that non-anti-TNF-α biologics did not exhibit significantly different efficacy and safety in the treatment of PsA. Notably, secukinumab 300 mg was ranked the highest for the American College of Rheumatology 20% improvement criteria (ACR20) response rate in the overall population and in the analyzed subpopulations and was the safest drug in terms of any adverse events. The overall risk of serious adverse events was lowest with ustekinumab 90 mg.